The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and ...

Shares of Regeneron Pharmaceuticals Inc. slipped 4.06% to $634.14 Tuesday, on what proved to be an all-around favorable ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

After every meal, the intestines perform an action called peristalsis - moving food through their hollow interiors with coordinated contractions and relaxations of the smooth muscle.

Biotech stocks took a hit after President Trump’s tariff comments spooked investors harder than a surprise lab result. Amgen led the sector’s dip with a 2.39% drop, while Regeneron and Merck also slid ...

Research in mice identifies protein responsible for regulating gut movement in response to pressure, exercise, and ...

UnitedHealth Group's pharmacy benefit manager, Optum Rx, said on Wednesday it would ease requirements to get insurance ...

Bispecific antibodies (BsAbs) have emerged as a transformative class of biologics, offering dual-targeting mechanisms that ...

A treat-to-target study of upadacitinib in atopic dermatitis showed that dosing can be adjusted depending on early patient ...

The long-running legal dispute between Amgen and Sanofi/Regeneron on two key patents covering the use of PCSK9 inhibitors to lower cholesterol has come to an end, with Sanofi emerging as the victor.